Severin Schwan, Roche CEO (Sebastien Bozon/AFP via Getty Images)
October 18, 2022 10:58 AM EDTUpdated 02:10 PM
R&D

Roche cuts PhII eye dis­ease pro­gram, one day af­ter an­oth­er biotech flopped in same in­di­ca­tion

Paul Schloesser

Associate Editor

Right af­ter NGM failed to meet the pri­ma­ry end­point in a Phase II eye dis­ease tri­al, one of the Big Phar­mas de­cid­ed to re­move a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times